ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
| Condition(s) | Acute Hepatic Porphyria |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies. |
| Who can participate | Inclusion Criteria: * Documented diagnosis of AHP, per physician's determination Exclusion Criteria: * Currently enrolled in a clinical trial for any investigational agent |
| Ages | 12 Years |
| Sex | All |
| Lead sponsor | Alnylam Pharmaceuticals |
| Locations | Birmingham, Alabama, United States; Gilbert, Arizona, United States; San Francisco, California, United States; Baltimore, Maryland, United States; Boston, Massachusetts, United States; Minneapolis, Minnesota, United States (+24 more sites) |
| Start date | 2021-04-26 |
| NCT ID | NCT04883905 |
| Official listing | https://clinicaltrials.gov/study/NCT04883905 |